54 results about "Opioid use disorder" patented technology

An apparatus for generating currents in biological tissue is provided. The apparatus comprises an electrical source capable of generating an electric field across a region of tissue and means for altering the impedance of the tissue relative to the electric field, whereby an altered current is generated. The means for altering the impedance may be a chemical source, optical source, mechanical source, thermal source, or electromagnetic source. The system can be used to provide stimulation safely and effectively in human transcranial use. The currents are used for stimulating tissues and treating diseases, such as for example Parkinson's Disease, Chronic Pain, Depression, and / or Opioid Use Disorder.

The disclosure is directed to sustained-release buprenorphine formulations that provide long-term, therapeutic levels of buprenorphine for the treatment of pain and the maintenance treatment of opioid use disorders, such as opioid dependence.

The present disclosure provides methods of treating opioid use disorder in a patient in need thereof by intravenously administering to the patient a therapeutically effective amount of ibogaine or pharmaceutically acceptable salt thereof.

The disclosure is directed to sustained-release buprenorphine formulations that provide long-term, therapeutic levels of buprenorphine for the treatment of pain and the maintenance treatment of opioid use disorders, such as opioid dependence.

Described are compositions and methods for increasing opioid therapy efficacy and ameliorating opioid use disorder. The compositions and methods target Ptchd1 or neuronal cholesterol.

Described are compositions and methods for treating pain and / or increasing opioid therapy efficacy and ameliorating opioid use disorder. The compositions and methods target Gαg / 11 signaling.

The present invention provides a compound having the structure:or a pharmaceutically acceptable salt or ester thereof, and methods of using the compound to treat pain, depressive disorders, mood disorders, anxiety disorders, opioid use disorder, and opioid withdrawal symptoms.

A system comprises data processing hardware and memory hardware in communication with the data processing hardware, the memory hardware storing instructions that when executed on the data processing hardware cause the data processing hardware to perform operations comprising executing a prescription digital therapeutic configured to treat symptoms associated with opioid use disorder in a patient, wherein executing the prescription digital therapeutic comprises receiving a plurality of inputs associated with the patient from one or more of (i) first sensors associated directly with the patient and (ii) second sensors associated with a patient electronic device, wherein the plurality of inputs represent a level of opioid withdrawal associated with the patient, weighting the plurality of inputs associated with the patient to provide a plurality of weighted inputs, determining a recommended dosage of a buprenorphine-containing product for the patient based on the plurality of weighted inputs, and instructing an administration unit to administer the recommended dosage of the buprenorphine-containing product to the patient.

Provided herein are compounds of Formula (I), (II), (III), or pharmaceutically acceptable salt, prodrug, or stereoisomer thereof, and compositions thereof, wherein R1, R1′, R2, R2′, R3, R4, R5, R5′, R6, R7, R9, R9′, R9″, X, and Z are defined herein. The disclosed compounds are useful for treating various conditions, including alcoholism, substance abuse disorder, and opioid use disorder

Provided is an injectable sustained release pharmaceutical formulation, including 3-acyl-naltrexone or a pharmaceutically acceptable salt thereof, a biocompatible organic solvent, and optionally a biocompatible polymeric material. Also provided is a method for treating opioid use disorder or alcoholism, including administering the injectable sustained release pharmaceutical formulation to a subject in need thereof. The pharmaceutical formulation provides a sustained release profile after one single injection, and the plasma levels of naltrexone in minipigs could provide a sustained release for 2 months.

Provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt thereof. Further disclosed are nanoparticles comprising one of the compounds and methods of using the same for treating drug addiction, drug dependence, drug overdose, opioid use disorder, pain, chronic pain, fibromyalgia, arthritis, or obesity.

Provided herein are compounds of Formula (I) or pharmaceutically acceptable salts thereof. Further disclosed are nanoparticles comprising one of the compounds and methods of using the same to treat drug addiction, drug dependence, drug excess, opioid use disorder, pain, chronic pain, fibromyalgia, arthritis, or obesity. (I)

The present disclosure relates to methods for treating subjects having a substance use disorder (SUD) with 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 negative allosteric modulators. Specifically, in some embodiments, this disclosure relates to methods of treating a subject having SUD who is at risk of relapse to alcohol use. In some embodiments, this disclosure relates to methods of promoting remission in a subject having SUD. In some embodiments, the SUD is alcohol use disorder (AUD), opioid use disorder (OUD), or a stimulant use disorder such as cocaine use disorder (CUD).

Provided is an injectable sustained release pharmaceutical formulation, including 3-acyl-naltrexone or a pharmaceutically acceptable salt thereof, a biocompatible organic solvent, and optionally a biocompatible polymeric material. Also provided is a method for treating opioid use disorder or alcoholism, including administering the injectable sustained release pharmaceutical formulation to a subject in need thereof. The pharmaceutical formulation provides a sustained release profile after one single injection, and the plasma levels of naltrexone in minipigs could provide a sustained release for 2 months.

A method of treating opioid use disorder (OUD) or alcohol use disorder (AUD) includes administering a pharmaceutically effective amount of a topical composition comprising an anhydrous suspension including naltrexone to an oral cavity of a subject for oral absorption therein. The topical composition is formulated to self-emulsify in an aqueous environment of the oral cavity.

The disclosure provides, inter alia, opioid haptens, opioid hapten conjugates, opioid vaccines, methods of treating or preventing opioid use disorder, methods of treating opioid overdose, and methods of generating and / or isolating antibodies selective for opioids.

A composition and method for treatment of opioid use disorder (OUD) is provided by expressing a novel mu receptor mutant, LAMuOR (Low Affinity Mu Opioid Receptor), with reduced binding affinity for opioids such that it is activated only by the high concentration of exogenous opioids encountered in OUD but not by the low concentrations of endogenous opioids that occur physiologically. When expressed in specific brain circuits, these low-affinity mu opioid receptors can suppress reward-related neuronal activity specifically in the presence of opioids of abuse, thereby reducing abuse potential.

The disclosure provides methods of treating opioid use disorder in a human by rapid induction with monthly injectable extended release buprenorphine, and to rapid induction dosage regimens for treating opioid use disorder. The methods provide increased treatment retention compared to standard of care methods.

The present invention relates to compounds of general formula (I), wherein the groups R1, R2 and n are defined as in claim 1, which are ghrelin O-acyl transferase (GOAT) inhibitors for use in the treatment of substance use disorder (SUD,) in particular for use in the treatment of opioid use disorder (OUD) or stimulant use disorder (StimUD), in patients with high impulsivity.

Compositions comprising at least 10% of a compound of formula (I) by weight, at least 10% of a compound of formula (II) by weight, or at least 10% by weight of a combination of a compound of formula (I) and a compound of formula (II), are disclosed herein. Methods for administering the compositions are disclosed herein. The methods can be used to produce a calming effect, produce an analgesic effect, manage pain, treat cough, treat anxiety, treat depression, treat opioid use disorder, and / or to treat opioid withdrawal in a subject.

Rapid-release formulations for administering Levo-alpha-acetylmethadol (LAAM), norLAAM and dinorLAMM and, optionally, magnesium, are provided. The formulations include solid i) core-shell oral dosage forms delivered in capsules or tablets, and ii) electrospun nano / microfiber buccal film dosage forms. Methods of the use of the formulations to treat opioid use disorder (OUD) and pain are also provided.

A method of treating opioid use disorder involves administering a selective butyrylcholinesterase (BChE) inhibitor.

A combination therapy for use in treatment of substance abuse disorders, including alcohol use disorder (AUD) and opioid use disorder (OUD), includes both mitragynine (MG) and naltrexone (NTX). NTX is understood to be a mu opioid antagonist that is expected to block MG's analgesic effects. However, combining MG and NTX therefore results in a unique, unexpected, and beneficial treatment that decreases alcohol self-administration to a greater extent than either alone.

Electrostimulation systems and methods are contemplated in which a high current level, charge balanced alternating current electrical signal is generated for delivery to the cortex region of a patient's brain for treating opioid use disorder and substance use disorder. By stimulating this region of the brain with a charged balanced stimulation current with a stimulation current envelope defining one or more series of pulses at particular frequencies and durations designed to evoke metabolic response in the neurons, significant improvements in efficacy and reductions in patient discomfort may be achieved relative to earlier methods of transcranial electrical stimulation. Further advantages, especially in promoting neural entrainment, may be realized as well via utilizing multiple series of pulses at different frequencies, and via the dynamic adjustment of the stimulation waveform via incorporation of feedback signals in order to maintain charge balance in real-time.

Disclosed herein are compositions and methods for treating opioid use disorders, including opioid overdose with combinations including methocinnamox and at least one additional opioid modulators, for example opioid agonists, partial agonists, antagonists and allosteric modulators. The compositions and methods are also useful for treating alcohol use disorder, and other disorders associated with endogenous opioid production.

The present invention provides a composition which comprises a compound which is a mixture of deuterium containing and non-deuterium containing molecules having the structure:wherein R1 iswherein at least one of H1, H2 or H3 is a deuterium-enriched —H site, orwherein at least one of H1, H2, H3, H4 or H5 is a deuterium-enriched —H site,or a pharmaceutically acceptable salt of the compound, and methods of using the composition to treat pain, depressive disorders, mood disorders, anxiety disorders, opioid use disorders, and opioid withdrawal symptoms.

The present invention provides a compound having the structure: or a pharmaceutically acceptable salt or ester thereof, and methods of using the compound to treat pain, depressive disorders, mood disorders, anxiety disorders, opioid use disorder, and opioid withdrawal symptoms.

The disclosure provides a dosage regimen using sustained-release buprenorphine formulations to produce therapeutic levels of buprenorphine in patients for the treatment of pain or opioid use disorders.

Compounds having opioid characteristics are provided that can be used for various therapeutic methods including the treatment of pain and opioid use disorders, and compounds having opioid antagonist properties that can be used to treat opioid overdoses. These compounds include agonists and antagonists having selective activity toward more one or more opioid receptors. Such compounds can be full or partial agonists, or can be antagonists lacking agonist properties toward delta and kappa opioid receptors. The partial agonists can diminish side effects associated with traditional opioid medications, and the antagonists can overcome respiratory depression caused by potent narcotics. Structurally these compounds include constrained piperidines with alkenyl or cyanoalkyl groups, as well as other substituents providing desired properties.

An apparatus for generating currents in biological tissue is provided. The apparatus comprises an electrical source capable of generating an electric field across a region of tissue and means for altering the impedance of the tissue relative to the electric field, whereby an altered current is generated. The means for altering the impedance may be a chemical source, optical source, mechanical source, thermal source, or electromagnetic source. The system can be used to provide stimulation safely and effectively in human transcranial use. The currents are used for stimulating tissues and treating diseases, such as for example Parkinson's Disease, Chronic Pain, Depression, and / or Opioid Use Disorder.